CUMBERLAND PHARMACEUTICALS INC — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
On July 1, 2026, Cumberland Pharmaceuticals closed the sale of its six FDA-approved branded drugs (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ) and related assets to Nuvo Pharmaceuticals (Ireland) DAC, a subsidiary of Apotex Inc., for $100 million cash. The transaction, approved by shareholders with 99%+ support, extinguished Cumberland's $5.3 million revolving credit facility with Pinnacle Bank. Cumberland retained its ifetroban rare-disease pipeline and majority stake in Cumberland Emerging Technologies Inc., shifting from commercial products to development-stage operations.
Why this rating
Large relative to company size (~$29.4M market cap): $100M proceeds nearly 3.4x the market cap. Strategic transformation—divests majority revenue base (~$40M annual 2025), but provides near-term capital to fund pipeline development. Will trigger discontinued-operations accounting. Material but not going-concern-level; leaves ongoing viable rare-disease focus.
Extracted items
- 1.01 material agreement
- 1.02 agreement termination
- 2.01 acquisition/disposition
- 5.02 exec change
- 8.01 other event
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.